Agilent Technologies opened a Dissolution Center of Excellence in Craven Arms, United Kingdom, on Oct. 12, 2022.
Agilent Technologies opened a Dissolution Center of Excellence in Craven Arms, United Kingdom, on Oct. 12, 2022, consolidating all of the company’s activities in the area of dissolution under one roof.
According to a company press release, the modernized facility will house the company’s core dissolution business, which includes R&D, quality, support, applications, marketing, and other segments. Additionally, the dissolution center will be a hub for Agilent’s global dissolution customers where they will be able to access a variety of tools, such as education, training, application development, and both on-site and virtual demonstrations.
“The growth in our dissolution business has really driven the need for this larger facility,” said Steve O’Donohue, director at the Craven Arms site, in the press release. “Our new flagship site will enable us to develop a truly unified approach to dissolution for the future. The location will also facilitate greater innovation and manufacturing capabilities to support Agilent’s digital lab initiatives.”
“By centering all dissolution activities in the UK, customers from all time zones will have improved access to our team of experts, with the latest technology to virtually connect for education, training, troubleshooting, and all other types of dissolution testing assistance,” added Dan Spisak, dissolution marketing manager at Agilent, in the press release.
Source: Agilent
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.